Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02041169
Other study ID # 35RC13-9907-CLASH
Secondary ID 2013-A01381-4413
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date September 2018

Study information

Verified date May 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths. In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied. This study is a prospective, cross-sectional study in exercise pathophysiology. The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients. Secondary goals are : 1. To determine the nature of the relationship between the recovery duration and subsequent walking performance. 2. To study the relationship between exercise ischemia, pain evolution and previous recovery duration. 3. To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration. 4. To study the influence of recovery duration on walking capacity from community-based measurement.


Description:

It is expected to determine for the first time an optimal recovery duration that would maximize the walking capacity of LEPAD patients. In the medium term : - To give indications to the LEPAD patients to manage their pain in the community without lower their physical activity. - To limit the functional decline of LEPAD patients. - To influence the quality of life and cardiovascular mortality. This would deserve furthers studies.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date September 2018
Est. primary completion date July 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old - Insured under the French social security system (according to French law) - Presence of lower-extremity peripheral artery disease, defined by: - A resting ankle-brachial index (ABI) = 0.90 - OR if resting ABI > 0.90 and < 1.00, a decrease in recovery ankle systolic pressure or in recovery ABI from treadmill exercise higher than 30% or 20%, respectively (AHA recommendations). - OR if resting ABI > 1.40, a toe pressure index = 0.70 - Maximal walking distance on treadmill (3.2 km/h, 10% grade) < 500m (a) - Complain of exertional lower limbs pain that can begin or not at rest, causes the participant to stop walking and relieves or lessens within 10 minutes of rest (assessed using the San Diego questionnaire AND confirmed during treadmill testing) (b) 1. As assessed during the medical appointment. 2. According to our inclusion criteria, patients' leg symptoms that fell within the following leg symptom categories could be included in the study: i) Intermittent claudication. Patients that experience exertional calf pain that does not begin at rest and that forces them to stop walking and that relieves or lessens within 10 minutes of rest; ii) Atypical exertional leg pain/stop. This category can encompass diverse situations of exertional leg symptoms. In the present study, patients in this category were included if they experience exertional pain that does not begin at rest and that forces them to stop walking, but that do not involve only the calf(s) but also thigh(s) and/or buttock(s). Further, the exertional leg pain relieves or lessens within 10 minutes of rest; iii) Leg pain on exertion and rest. In this category, patients sometimes experience exertional leg pain at rest when they are standing still or sitting. On exertion, patients also experience a walking pain as described above. As reminded by Criqui et al., this category of patients with "pain at rest" should not be confused with patients that experience "rest pain", which usually refers to patients with such severe advanced PAD that ischemic pain is present even at rest. Patients with ischemic rest pain were not included in the study. Non-Inclusion criteria - Exercise limitation due to symptoms not related to an arterial insufficiency in the lower limbs (e.g., dyspnea, angina pectoris) - Contraindication for walking (Abdominal aortic aneurysm > 4 cm) - Myocardial infarction and no stroke in the last 3 months - Critical limb ischemia, amputation. - Pregnant women - Adult subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law). - Patient living more than 50 km from the university hospital - Patient unable to understand the instructions of the study

Study Design


Intervention

Other:
Subsequent walking performance
Subsequent walking performance

Locations

Country Name City State
France Rennes University Hospital Rennes Brittany

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

References & Publications (4)

Chaudru S, Jehannin P, de Mullenheim PY, Klein H, Jaquinandi V, Mahe G, Le Faucheur A. Using wearable monitors to assess daily walking limitations induced by ischemic pain in peripheral artery disease. Scand J Med Sci Sports. 2019 Nov;29(11):1813-1826. do — View Citation

de Mullenheim PY, Chaudru S, Mahe G, Prioux J, Le Faucheur A. Clinical Interest of Ambulatory Assessment of Physical Activity and Walking Capacity in Peripheral Artery Disease. Scand J Med Sci Sports. 2016 Jul;26(7):716-30. doi: 10.1111/sms.12512. Epub 20 — View Citation

de Mullenheim PY, Rouviere L, Emily M, Chaudru S, Kaladji A, Mahe G, Le Faucheur A. "Should I stay or should I go now?" Recovery time effect on walking capacity in symptomatic peripheral artery disease. J Appl Physiol (1985). 2021 Jul 1;131(1):207-219. do — View Citation

Donnou C, Chaudru S, Stivalet O, Paul E, Charasson M, Selli JM, Mauger C, Chapron A, Le Faucheur A, Jaquinandi V, Mahe G. How to become proficient in performance of the resting ankle-brachial index: Results of the first randomized controlled trial. Vasc M — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking 32 days
Other Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements. Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements 32 days
Primary Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses. Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses. 32 days
Secondary Coefficient of determination determined from different curves fitting Coefficient of determination determined from different curves fitting 32 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400395 - Clinical Trial for GNX80 in Intermittent Claudication Phase 4
Active, not recruiting NCT02341716 - Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication N/A
Completed NCT00822172 - Evaluation of Cilostazol in Combination With L-Carnitine Phase 4
Recruiting NCT00538408 - Whole Body Magnetic Resonance Angiography in Ischemic Patients N/A
Completed NCT00618670 - Home-based vs. Supervised Exercise for People With Claudication N/A
Completed NCT00388128 - Caffeine and Intermittent Claudication Phase 3
Recruiting NCT00146666 - Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD) Phase 2
Completed NCT00134277 - Trial Comparing Different Medical Devices for Infragenual Dilatation N/A
Completed NCT01256775 - Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD) Phase 2
Completed NCT00029991 - Extract of Ginkgo Biloba (EGB 761) and Vascular Function Phase 1/Phase 2
Recruiting NCT06299956 - Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark N/A
Not yet recruiting NCT05335161 - A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease Phase 1
Completed NCT04390282 - Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication N/A
Completed NCT03271710 - Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System N/A
Completed NCT02380794 - Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule Phase 2
Active, not recruiting NCT02276937 - Randomized Phase IIb Trial of DVC1-0101 Phase 2
Completed NCT02097082 - Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System N/A
Recruiting NCT00539266 - Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Phase 2/Phase 3
Completed NCT00071266 - The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC Phase 3
Completed NCT00300690 - Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Phase 4